Sumain Faisal

Coursera’s Upbeat Outlook Drives Stock Higher

Coursera shares soar over 32% as strong Q2 results and rising consumer momentum boost long-term growth expectations. Latest Ratings for COUR Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Feb 2022 Telsey Advisory Group Maintains Outperform Feb 2022 Keybanc Maintains Overweight View More Analyst Ratings for COUR View the Latest Analyst Ratings…

Read More

Gilead’s Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates. Latest Ratings for GILD Date Firm Action From To Mar 2022 Barclays Maintains Underweight Mar 2022 RBC Capital Maintains Outperform Feb 2022 BMO Capital Downgrades Outperform Market Perform View More Analyst Ratings…

Read More